Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Cocozaki A, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: to f. Mol Cancer Ther. 2024 May 8. doi: 10.1158/1535-7163.MCT-23-0613. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38714351
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Cocozaki A, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: to f. Mol Cancer Ther. 2024 Jun 12:OF1-OF16. doi: 10.1158/1535-7163.MCT-23-0613. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38863225
EHMT1/2 inhibition promotes regression of therapy-resistant ovarian cancer tumors in a CD8 T cell-dependent manner.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Lin S, Villagomez FR, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: to f. Mol Cancer Res. 2024 Aug 13. doi: 10.1158/1541-7786.MCR-24-0067. Online ahead of print. Mol Cancer Res. 2024. PMID: 39136655
Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation.
Mulholland M, Depuydt MAC, Jakobsson G, Ljungcrantz I, Grentzmann A, To F, Bengtsson E, Jaensson Gyllenbäck E, Grönberg C, Rattik S, Liberg D, Schiopu A, Björkbacka H, Kuiper J, Bot I, Slütter B, Engelbertsen D. Mulholland M, et al. Among authors: to f. Cardiovasc Res. 2024 May 7;120(6):581-595. doi: 10.1093/cvr/cvae046. Cardiovasc Res. 2024. PMID: 38563353 Free PMC article.
Expanding the molecular and phenotypic spectrum of CTLA-4 insufficiency.
Duke S, Maiarana J, Yousefi P, Burks E, Gerrie S, Setiadi A; BC Children's and St Paul's Hospital Members; Hildebrand KJ, James E, Turvey SE, Markle JG, Biggs CM. Duke S, et al. Pediatr Allergy Immunol. 2024 Feb;35(2):e14077. doi: 10.1111/pai.14077. Pediatr Allergy Immunol. 2024. PMID: 38351878 No abstract available.
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
Herman GA, O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Musser BJ, Davis JD, Turner KC, Mahmood A, Hooper AT, Hamilton JD, Parrino J, Subramaniam D, Baum A, Kyratsous CA, DiCioccio AT, Stahl N, Braunstein N, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. Herman GA, et al. Lancet Infect Dis. 2022 Oct;22(10):1444-1454. doi: 10.1016/S1473-3099(22)00416-9. Epub 2022 Jul 5. Lancet Infect Dis. 2022. PMID: 35803290 Free PMC article. Clinical Trial.
51 results